WO2016137352A1 - Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией - Google Patents
Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией Download PDFInfo
- Publication number
- WO2016137352A1 WO2016137352A1 PCT/RU2015/000120 RU2015000120W WO2016137352A1 WO 2016137352 A1 WO2016137352 A1 WO 2016137352A1 RU 2015000120 W RU2015000120 W RU 2015000120W WO 2016137352 A1 WO2016137352 A1 WO 2016137352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ear
- otitis media
- articaine
- pharmaceutical composition
- benzalkonium chloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the group of inventions relates to medicine and can be used in the treatment of otitis media and other inflammatory diseases in the ear.
- Otitis is a disease that is an inflammatory process in the ear.
- the human ear consists of the outer ear, middle ear and inner ear.
- otitis externa is the boil of the external auditory canal.
- Diffuse external otitis is represented by a large group of inflammatory diseases of a bacterial viral, fungal nature.
- Middle ear diseases are found in representatives of all age groups and have important clinical and social significance. The variety of pathogenetic mechanisms of these diseases is determined by the characteristics of the anatomy and physiology of the middle ear, the etiological factor in each case, the state of the body's immune system, etc. When determining the nosological form, the predominant development of the process in one or another department of the middle ear is usually taken into account.
- the term "acute otitis media” is used to denote predominant inflammation in the tympanic cavity, the development of acute inflammation mainly in the auditory tube - eustachitis, in the mastoid process - mastoiditis.
- ear drops are mainly based on aminoglycoside antibiotics (Sofradex, Garazon, Anauran).
- the main groups of microorganisms that cause inflammatory diseases of the ear are sensitive to antibiotics of the aminoglycoside class.
- aminoglycosides have potential ototoxicity, which limits their use only to external otitis media and nonperforated forms of otitis media (Balyasinskaya G.L. Ear drops of otof and polydex in the treatment of children with acute middle and external otitis media // Bulletin of Otorhinolaryngology. 2003. 3. P. 53-54.).
- a pharmaceutical composition for treating diseases of the ear containing a therapeutic agent, which, in particular, may be an anesthetic, for example, articaine, or an anti-inflammatory agent, in particular phenazone.
- a therapeutic agent which, in particular, may be an anesthetic, for example, articaine, or an anti-inflammatory agent, in particular phenazone.
- compositions of the claimed pharmaceutical composition proposed by the authors for the first time.
- the aim of the present invention is to provide a new effective pharmaceutical composition for the treatment of otitis media.
- the technical result of the present invention is to increase the effectiveness (enhancing the clinical effect) of the treatment of otitis media and to provide an effective and stable pharmaceutical composition that can be used to treat otitis media.
- Embodiments of the present invention relate to a pharmaceutical composition for treating otitis media comprising at least phenazone or propiphenazone and articaine, as well as benzalkonium chloride.
- Embodiments of the present invention also relate to a method for treating otitis media and a method for preparing a pharmaceutical composition for treating otitis media.
- FIG. 1 shows a photograph after scarification of an experimental rabbit ear receiving formulation No. 1 prior to application of the formulation.
- FIG. Figure 2 shows a photograph after scarification of an experimental rabbit ear receiving formulation No. 1, one day after the first application of the formulation.
- FIG. Figure 3 shows a photograph after scarification of an experimental rabbit ear receiving formulation No. 1, two days after the first application of the formulation.
- FIG. Figure 4 shows a photograph after scarification of an experimental rabbit ear treated with JNs 1 three days after the first application of the formulation.
- FIG. Figure 5 shows a photograph after scarification of an experimental rabbit ear receiving N ° 2 formulation before application of the formulation.
- FIG. Figure 6 shows a photograph after scarification of an experimental rabbit ear receiving N ° 2 formulation, one day after the first application of the formulation.
- FIG. Figure 7 shows a photograph after scarification of an experimental rabbit ear receiving N ° 2 formulation two days after the first application of the formulation.
- FIG. Figure 8 shows a photograph after scarification of an experimental rabbit ear receiving jN 2 formulation three days after the first application of the formulation.
- FIG. Figure 9 shows a photograph after scarification of an experimental rabbit ear receiving formulation No. 3 prior to application of the formulation.
- FIG. 10 shows a photograph after scarification of an experimental rabbit ear receiving a formulation of ⁇ ° 3, one day after the first application of the formulation.
- FIG. 1 1 shows a photograph after scarification of an experimental rabbit ear treated with JNs 3 two days after the first application of the formulation.
- FIG. Figure 12 shows a photograph after scarification of an experimental rabbit ear receiving N ° 3 formulation three days after the first application of the formulation.
- FIG. 13 is a photograph after scarification of a rabbit control ear.
- FIG. 14 is a photograph after scarification of the control rabbit ear one day later.
- FIG. 15 shows a photograph after scarification of the control rabbit ear after two days.
- FIG. 16 shows a photograph after scarification of the control rabbit ear after three days.
- FIG. 17-23 presents the source data of an enzyme immunoassay for cytokines IL- ⁇ and TNF-a
- FIG. 24 shows the level of TNF-a in the supernatants of activated macrophages (MF) after 6 hours of incubation, depending on the concentration of benzalkonium chloride.
- FIG. 25 shows the level of TNF- ⁇ in the supernatants of activated macrophages (MF) after 24 hours of incubation, depending on the concentration of benzalkonium chloride.
- FIG. Figure 26 shows the effect on the level of IL- ⁇ synthesis in the supernatants of activated MFs after 6 hours of incubation, depending on the concentration of benzalkonium chloride.
- FIG. Figure 27 shows the effect on the level of IL- ⁇ synthesis in the supernatants of activated MFs after 24 hours of incubation, depending on the concentration of benzalkonium chloride.
- Phenazone (trademark: “Antipyrine”) is a drug, analgesic and antipyretic from the pyrazole group.
- Phenazone was one of the first synthetic analgesics derived from pyrazolone, which found application in medicine (1884). With the receipt of other analgesics, they began to use it relatively rarely. Phenazone is currently not widely used.
- phenazone has an analgesic, antipyretic and, to some extent, anti-inflammatory effect.
- drugs of this group are close to salicylic acid derivatives.
- Derivatives of pyrazolone reduce the permeability of capillaries and prevent the development of an inflammatory reaction.
- Phenazone has a moderate analgesic, antipyretic and anti-inflammatory effect. When applied topically, there is some hemostatic effect. It is used for neuralgia, colds.
- Propiphenazone is an analgesic and antipyretic from the pyrazolone group, is a phenazone derivative and has similar analgesic and antipyretic properties.
- propiphenazone as an active component of the pharmaceutical composition for external or local use is not known from the prior art.
- Articain (Articaine) (trade name - Ultracain) is a drug with high anesthetic activity.
- compositions comprising articaine hydrochloride are described within the scope of the present invention.
- Articaine is a local anesthetic that is used for infiltration and conduction anesthesia.
- the drug has a high analgesic effect, 2 times stronger than lidocaine and 6 times procaine.
- Anesthetic penetrates through the membrane into the nerve fiber, releasing a base with lipophilic properties as a result of hydrolysis in a slightly alkaline environment of body tissues (in an acidic environment, the effect of the drug decreases).
- ultracain interacts with nerve receptors, blocks the entry of Na + into the cell in the depolarization phase and blocks the conduction of impulses along the nerve fiber.
- Anesthesia occurs immediately after administration and lasts from 1 to 5 hours.
- the active substance is articaine hydrochloride (4-methyl-3 [2-propylaminopropionamido] -2-thiofecarboxylic acid methyl ester) + adrenaline hydrotartrate (epinephrine).
- Benzalkonium chloride an antiseptic drug, also has an antifungal, antiprotozoal, local contraceptive (spermatocidal) effect; inactivates viruses that cause herpes simplex (Herpes simplex).
- Alkyldimethylbenzylammonium chloride (alkylbenzyldimethylammonium chloride).
- the spermatocidal effect is due to the ability to damage sperm membranes (at the beginning of flagella, then the head), which makes it impossible to fertilize a damaged sperm.
- the effect develops after 8-10 minutes (tablets), 5 minutes (vaginal suppositories), 3 minutes (cream) or immediately after introduction into the vagina (tampon), in vitro is active against Neisseria gonorrhoeae, Chlamydia spp., Trichomonas vaginalis, Human herpesvirus 2, Staphylococcus aureus. He has effects on Mycoplasma spp.
- Gardnerella vaginalis Candida albicans, Haemophilus ducreyi and Treponema pallidum. In vivo exhibits some activity in the prevention of certain sexually transmitted diseases. Does not affect the normal microflora of the vagina (including the doderlein stick) and the hormonal cycle.
- Propylene glycol - is used as a filler and the main solvent of the substance propiphenazone (in combination with glycerin). Also, in view of the absence of preservatives in the claimed compositions, together with benzalkonium chloride, it can act as a preservative, since it has a bactericidal effect.
- Glycerin - filler, cosolvent also acts as a substitute for water, reducing the amount of solvent used (water) in which the active substance propiphenazone is insoluble, thereby increasing the stability of the composition during storage. Due to its viscosity, it increases the overall viscosity of the composition, generally contributing, inter alia, to improving the rheological properties of the composition and the process of dispensing drops when used.
- the main aspect of the implementation of the present invention is a pharmaceutical composition having analgesic, anesthetic, antiseptic and anti-inflammatory effects, which can be used to treat otitis media, in particular, external and secondary otitis media, as well as other inflammatory diseases of the ear, containing at least: as an analgesic agent, phenazone or propiphenazone; as an anesthetic agent articaine; and as an antiseptic and anti-inflammatory agent benzalkonium chloride.
- compositions having analgesic, anesthetic and bactericidal action containing at least: as an analgesic agent phenazone or propiphenazone in an amount of 4% may; as an anesthetic agent, articaine in an amount of 2% in May; and as an antiseptic agent of benzalkonium chloride in an amount of from 0.05 to 0.2% May.
- compositions having analgesic, anesthetic and bactericidal action containing at least: as an analgesic agent phenazone or propiphenazone, in particular, in an amount of 4% may; as an anesthetic agent, articaine, in particular, in an amount of 2% may; as an antiseptic agent of benzalkonium chloride, in particular, in an amount of from 0.05 to 0.2% May; and optionally optionally containing propylene glycol as an excipient, in particular in an amount of from 44 to 60 %% of May, and additionally containing glycerin as an auxiliary substance, in particular in an amount of from 20 to 30 %% of May
- Another aspect of the implementation of the present invention is a pharmaceutical composition according to any of the above aspects of the implementation of the present invention, characterized in that it is an ear drop.
- Another aspect of the implementation of the present invention is a method for producing a pharmaceutical composition comprising at least propiphenazone, articaine and benzalkonium chloride, comprising:
- Another aspect of the implementation of the present invention is the above-described method for producing a pharmaceutical composition comprising at least propiphenazone, articaine and benzalkonium chloride, characterized in that the mixing is intense.
- Another aspect of the present invention is the method described above for producing a pharmaceutical composition comprising at least propiphenazone, articaine and benzalkonium chloride, characterized in that the mixing of the obtained solution of propiphenazone and propylene glycol with the resulting solution of articaine, benzalkonium chloride and water is carried out under stirring for no more than 30 minutes.
- Another aspect of the present invention is the method described above for preparing a pharmaceutical composition comprising at least propiphenazone, articaine and benzalkonium chloride, characterized in that glycerol is added to the solution obtained by mixing with stirring for no more than 30 minutes.
- Another aspect of the implementation of the present invention is the above-described method for producing a pharmaceutical composition containing at least propiphenazone, articaine and benzalkonium chloride, characterized in that after the gradual addition of water to a predetermined volume, filtering is carried out, in particular through a sieve, in particular, nylon .
- Another aspect of the implementation of the present invention is a method for producing a pharmaceutical composition comprising at least phenazone, articaine and benzalkonium chloride, comprising:
- Another aspect of the present invention is the method described above for producing a pharmaceutical composition comprising at least phenazone, articaine and benzalkonium chloride, characterized in that the mixing is intense.
- Another aspect of the present invention is the method described above for preparing a pharmaceutical composition comprising at least phenazone, articaine and benzalkonium chloride, characterized in that glycerol is added to the solution obtained by stirring with stirring for no more than 30 minutes.
- Another aspect of the implementation of the present invention is the above-described method for producing a pharmaceutical composition containing at least phenazone, articaine and benzalkonium chloride, characterized in that after the gradual addition of water to a predetermined volume, filtering is carried out, in particular through a sieve, in particular, nylon .
- Another aspect of the present invention is a method of treating otitis media, comprising administering a pharmaceutical composition according to any of the above aspects of the present invention in the form of ear drops in the ear of a patient suffering from an inflammatory process in the ear.
- Another aspect of the present invention is a method of treating otitis media, comprising administering a pharmaceutical composition according to any of the above aspects of the present invention in the form of ear drops to an ear of a patient suffering from an inflammatory process in the ear, the inflammatory process in the ear being external or middle otitis media.
- Formulation N ° 4 propiphenazone 4% in May, articaine 2% in May, benzalkonium chloride 0.2% in May;
- the formulations ⁇ ° ⁇ 2 1-3 were tested for antiseptic and anti-inflammatory activity in animals.
- the anti-inflammatory and antiseptic effects of three ear-drop samples were evaluated by the wound healing effect of a skin defect in rabbits and morphological examination of smears from the wound surface.
- the nature and duration of wound healing showed a pronounced effect.
- the samples of ear drops have an anti-inflammatory effect.
- the main indication for developing ear drops is otitis media. Since there is no adequate model of these diseases in animals, the anti-inflammatory effect of three samples of ear drops was studied on the model of scarified skin wounds in experiments on rabbits. The main criteria for evaluating the effect of drugs were the nature and duration of wound healing, as well as morphological parameters of the wound discharge.
- the experiments were performed on male chinchilla rabbits weighing 2.5-3.0 kg.
- the animals were obtained from the Andreevka Branch of the Scientific Center “Biomedical Technologies” RAMS and kept in a vivarium according to the sanitary rules on a standard diet using dry granulated feed.
- Scarified skin wounds were reproduced in rabbits as follows. On the outer ear (taking into account the purpose of the drops as close as possible to the external auditory meatus) of each rabbit, several surface incisions were made with a scalpel on both sides on a plot of about 1 x 1 cm. After about 1 hour, a certain formulation of ear drops was applied to the wound surface on the right ear (hereinafter referred to as the “experimental ear”) of all experimental rabbits, according to the group number indicated above, in the amount of 2-3 drops. Drop applications were carried out twice with an interval of 24 hours until a dense scab was formed.
- control was the wound surface on the opposite left ear (hereinafter also referred to as the “control ear”), which was not treated.
- formulations N ° N ° 1-3 have a pronounced antiseptic and anti-inflammatory effect, which is manifested in a more rapid formation of a scab and faster healing of the wounds of an experienced ear.
- MFs sensitized peritoneal macrophages
- Activated MFs were isolated from rat peritoneal exudate 4 days after intraperitoneal injection of 5 ml of horse serum.
- the peritoneal cavity was washed with PBS (PanEco, Russia), then the resulting suspension was collected in centrifuge tube (CORNING, 50 ml). After centrifugation (Eppendorf, 5702RH, Germany), the supernatant was removed for 5 minutes at 200 rpm and the cell pellet was resuspended in growth medium RPMI-1640 (GIBCO) supplemented with 10% FBS (GIBCO), L-Glutamine and antibiotic / antimycotics (GIBCO) standard concentration.
- Mononuclear cells were counted in a Goryaev chamber using an Olympus microscope (Olympus SK 40, Japan), after which a cell suspension was prepared with a concentration of 1.6 x 10 6 cells / ml.
- the isolated MFs were plated in two 24-well plates. After two hours of incubation, non-adherent cells were removed and the wells were washed with warm Hanks solution (PanEco, Russia). Attached MFs comprise approximately 50-60% of the total number of planted mononuclear cells.
- test drugs The effect of the drug on sensitized MFs was studied in three dilutions. For this, on sterile conditions RPMI-1640 (GIBCO) supplemented with 1% FBS, L-Glutamine and an antibiotic / antimycotic, N ° N ° 1-3 at the indicated concentrations were prepared.
- the quantitative content of soluble cytokines IL- ⁇ and TNF- ⁇ in activated MF supernatants was determined by the standard method of solid-phase ELISA.
- the studies were performed with standard reagent kits for the ELISA Quantikine ELISA Rat TNF-a (Catalog Number RTA00) and Quantikine ELISA Rat IL- ⁇ (Catalog Number RLB00), manufactured by R&D Systems (Great Britain).
- the analysis was performed according to a standard protocol.
- the optical density was measured on an Anthos 2010 reader spectrophotometer (Austria) at a wavelength of 450 nm.
- the initial enzyme immunoassay data for both cytokines are shown in FIG. 17-23. Results.
- N ° N ° 1-3 formulations on the synthesis of IL- ⁇ and TNF-a by activated MFs in an in vitro model was investigated. Throughout the entire experiment, light microscopic observation of the state of the MF culture was performed. Visual inspection after 6 hours and 24 hours of cultivation revealed no morphological differences between the cells in the control and test wells. Cells in all wells had the same degree of spread, detritus was absent in the medium. From which we can conclude that the studied drugs do not cause a cytotoxic effect on cell culture during 24 hour incubation.
- FIG. 24 and 25 show the level of TNF-a in the supernatants of activated MFs after 6 hours and 24 hours of incubation, depending on the concentration of benzalkonium chloride.
- Co - control non-conditioned medium RPMI-1640 with 1% FBS.
- the concentration of TNF-a in comparison with the control groups K1 and K2 is reduced by an average of 30%.
- ⁇ 2 ⁇ ° 1-3 formulations equally inhibit the synthesis of TNF-a activated macrophages. After a day, to the end point of the study, this trend continues. From this we can conclude that the studied formulations equally inhibit the synthesis of TNF-a activated MF within 24 hours.
- FIG. 26 and 27 show the effect of the studied drugs on the level of synthesis of IL-1 ⁇ in activated MF supernatants.
- the concentration of IL- ⁇ tends to decrease after 6 hours of incubation.
- the concentration of IL- ⁇ decreases by about 2 times under the action of the K ° 1 and 2 formulations.
- the ⁇ ° 3 formulation to a lesser extent inhibits the synthesis of IL- ⁇ .
- the inhibitory effect of the studied drugs is weakened.
- the antiseptic activity of the formulations was studied in a liquid nutrient medium and in a dense nutrient medium.
- CD dense nutrient medium
- Standard bacterial suspensions corresponding to a density of 0.5 according to the MacFarland standard were prepared from diurnal cultures of test microorganisms tested grown on the corresponding solid nutrient media (chocolate and 5% blood agar with cardiac extract) . With a sterile cotton swab, the suspension was applied to a Petri dish with medium to determine the sensitivity. After drying for 5 minutes, 1 drop was applied to the surface of the nutrient medium with the test microorganism (20 ⁇ l) NeNs 4-6 formulations. The results were taken into account after 24-48 hours of incubation of the plates with crops in the zone of growth inhibition of the test microorganism.
- Formulations N ° 2 4-6 provide the death of S. aureus, M. catarrhalis, S. pneumoniae, S. pyogenes, H. influenzae after 60 minutes.
- formulations j ⁇ j ⁇ b 4-6 have pronounced antiseptic activity against S. aureus, M. catarrhalis, S. pneumoniae, S. pyogenes, H. influenzae.
- analgesic and anesthetic effect in this case is ensured, respectively, by phenazone or propiphenazone and articaine, as evidenced by less pronounced rabbit reactions to exposure to the scarified experimental ear.
- Preferred formulations in addition to phenazone (or propiphenazone), articaine and benzalkonium chloride additionally contain auxiliary substances. These formulations are the following formulations:
- the content of propylene glycol in the above formulations should be in the range from 40 to 60 %% in May.
- the glycerol content is from 20 to 30 %% in May.
- the rest is water.
- Such preferred formulations can be prepared as follows. Formulations N ° N ° 7-9 containing phenazone were obtained by dissolving phenazone, articaine and benzalkonium chloride in water at a temperature of 30-45 ° C with stirring until complete dissolution, followed by adding glycerol to the solution obtained by stirring while stirring until the homogeneity obtained by adding glycerol solution and the subsequent gradual addition of water to a predetermined volume with stirring. Mixing can be intense, i.e. such mixing, which would ensure a homogeneous solution. The addition of glycerol to the solution obtained by stirring can be carried out, in particular, with stirring for not more than 30 minutes.
- filtration can be carried out, in particular, through a sieve, for example, nylon.
- formulations a 10-12 containing propiphenazone were obtained by dissolving propiphenazone in propylene glycol at a temperature of 30-45 ° C with stirring until completely dissolved and dissolving articaine and benzalkonium chloride in water at a temperature of 30-45 ° C with stirring until completely dissolved after which the obtained solutions of propiphenazone with propylene glycol and articaine with benzalkonium chloride and water were mixed with stirring until a homogeneous solution was obtained by mixing, after which glycerol was added and to the solution obtained by mixing with stirring until the homogeneity of the solution obtained by adding glycerol is achieved, and then water is gradually added to a predetermined volume, also with stirring.
- mixing can be carried out intensively.
- Mixing the resulting solution of propiphenazone and propylene glycol with the resulting solution of articaine, benzalkonium chloride and water can be carried out with stirring for no more than 30 minutes.
- the addition of glycerol to the solution obtained by mixing can also be carried out with stirring for not more than 30 minutes.
- filtration can be carried out, in particular, through a sieve, for example, nylon.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15883501.7A EP3263103A4 (en) | 2015-02-26 | 2015-02-26 | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition |
PCT/RU2015/000120 WO2016137352A1 (ru) | 2015-02-26 | 2015-02-26 | Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией |
AU2015384252A AU2015384252A1 (en) | 2015-02-26 | 2015-02-26 | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition |
CA2976756A CA2976756A1 (en) | 2015-02-26 | 2015-02-26 | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition |
US15/552,667 US20180028494A1 (en) | 2015-02-26 | 2015-02-26 | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition |
EA201700424A EA033965B1 (ru) | 2015-02-26 | 2015-02-26 | Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2015/000120 WO2016137352A1 (ru) | 2015-02-26 | 2015-02-26 | Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016137352A1 true WO2016137352A1 (ru) | 2016-09-01 |
Family
ID=56788739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2015/000120 WO2016137352A1 (ru) | 2015-02-26 | 2015-02-26 | Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180028494A1 (ru) |
EP (1) | EP3263103A4 (ru) |
AU (1) | AU2015384252A1 (ru) |
CA (1) | CA2976756A1 (ru) |
EA (1) | EA033965B1 (ru) |
WO (1) | WO2016137352A1 (ru) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009142719A2 (en) * | 2008-05-19 | 2009-11-26 | Massachusetts Institute Of Technology | Tympanic membrane permeating ear drops and uses thereof |
US20120252720A1 (en) * | 2003-12-12 | 2012-10-04 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
WO2014179814A1 (en) * | 2013-05-03 | 2014-11-06 | Crews Thomas M | Method of treating disease by auricular anesthesia of cranial nerves |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080167281A1 (en) * | 2007-01-05 | 2008-07-10 | Preston David M | Combination Otic Formulation |
CN101584689B (zh) * | 2009-05-25 | 2011-03-16 | 中国人民解放军海军医学研究所 | 含安替比林和利多卡因的复方滴耳液及其制备方法 |
PT2552440T (pt) * | 2010-03-30 | 2019-01-10 | Helperby Therapeutics Ltd | Nova combinação e uso |
-
2015
- 2015-02-26 US US15/552,667 patent/US20180028494A1/en not_active Abandoned
- 2015-02-26 EP EP15883501.7A patent/EP3263103A4/en not_active Withdrawn
- 2015-02-26 EA EA201700424A patent/EA033965B1/ru not_active IP Right Cessation
- 2015-02-26 AU AU2015384252A patent/AU2015384252A1/en not_active Abandoned
- 2015-02-26 WO PCT/RU2015/000120 patent/WO2016137352A1/ru active Application Filing
- 2015-02-26 CA CA2976756A patent/CA2976756A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120252720A1 (en) * | 2003-12-12 | 2012-10-04 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
WO2009142719A2 (en) * | 2008-05-19 | 2009-11-26 | Massachusetts Institute Of Technology | Tympanic membrane permeating ear drops and uses thereof |
WO2014179814A1 (en) * | 2013-05-03 | 2014-11-06 | Crews Thomas M | Method of treating disease by auricular anesthesia of cranial nerves |
Non-Patent Citations (2)
Title |
---|
CHUESHOV V. I.: "Promyshlennaia tekhnologiia lekarstv.", KHARKOV: MTK- KNIGA IZDATELSTVO NFAU, 2002, pages 63 - 64, XP009501111 * |
See also references of EP3263103A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP3263103A4 (en) | 2018-03-14 |
EA201700424A1 (ru) | 2018-01-31 |
EA033965B1 (ru) | 2019-12-13 |
CA2976756A1 (en) | 2016-09-01 |
EP3263103A1 (en) | 2018-01-03 |
US20180028494A1 (en) | 2018-02-01 |
AU2015384252A1 (en) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108135745A (zh) | 用于伤口处理的有效新型快速沉积薄膜形成组合物 | |
CN109562094A (zh) | 增强抗微生物剂的组合物和方法 | |
CN104486945B (zh) | 用于治疗念珠菌病和曲霉菌属感染的化合物和方法 | |
US20200171077A1 (en) | Compositions and methods for treating and preventing bacterial infections | |
RU2432943C1 (ru) | Препарат для лечения мастита у коров в период лактации | |
RO122247B1 (ro) | Compoziţii farmaceutice de tizoxanidă şi nitazoxanidă | |
CN110507680A (zh) | 一种治疗面部痤疮、酒糟鼻的复方外用擦剂及其制备方法 | |
HU215443B (hu) | Többféle hatóanyagot tartalmazó gyógyszerkészítmények, főként hüvelykúp, baktericid, fungicid, protozoa- és vírusellenes kombinált hatással | |
KR100576646B1 (ko) | 티족사나이드 및 니타족사나이드의 약제학적 조성물 | |
JP2016508957A (ja) | カンジダ等の病原微生物による疾患用の医薬組成物 | |
WO2016137352A1 (ru) | Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией | |
CA2973255A1 (en) | Methods of destroying and preventing bacterial and fungal biofilm by amino acid infusion | |
Susilawati et al. | Activity of Karehau (Callicarpa longifolia Lamk.) leaves ethanolic extract as a wound healing | |
US20190381003A1 (en) | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using same composition | |
WO2009122404A2 (en) | Device for in situ production and topical administration of allicin | |
US11534412B2 (en) | Application of totarol and pharmaceutical composition containing totarol | |
RU2329790C1 (ru) | Лечебно-профилактическое средство, обладающее антибактериальным и спермицидным действием | |
RU2286800C1 (ru) | Антибактериальный наполнитель для женской гигиенической прокладки или тампона, способ его получения и использования | |
RU2367454C1 (ru) | Средство интимной гигиены "фемивит" | |
US9446024B2 (en) | Formulations for the treatment of vaginal disorders | |
RU2201219C2 (ru) | Фармакологическая композиция пролонгированного действия | |
US20060142243A1 (en) | Use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
CN113768950B (zh) | 一种宠物专用冲洗液及其制备方法 | |
RU2314795C2 (ru) | Ушные трубочки | |
Mileva et al. | Experimental treatment of recurrent otitis externa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15883501 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2976756 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201700424 Country of ref document: EA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015883501 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015384252 Country of ref document: AU Date of ref document: 20150226 Kind code of ref document: A |